Deeside based Reacta Biotech is on course to secure a market authorisation for its peanut diagnostic product within the next two years as global activity to treat peanut allergies accelerates. Insider Media reports Reacta expects Nestlé Health Sciences’ $2.6bn acquisition of Aimmune to accelerate demand for food allergy diagnostics as the California based biotech business … Continue reading Reacta Biotech making progress on peanut diagnostic product